Imricor Medical Systems Inc (ASX: IMR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Imricor Medical Systems Inc Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Imricor Medical Systems Inc (ASX: IMR)
Latest News
Share Gainers
Why DroneShield, Imricor, IAG, and Sayona Mining shares are roaring higher
Share Market News
ASX healthcare stock rockets 25% on big AI news
Healthcare Shares
Here's why the Imricor Medical (ASX:IMR) share price is surging 8% today
Healthcare Shares
Imricor Medical (ASX:IMR) share price spikes 6% after expanding trial sites
Share Market News
Why the Imricor (ASX:IMR) share price is racing 6% higher today
Healthcare Shares
Imricor (ASX:IMR) share price rises on latest update
Share Market News
Why the Imricor (ASX:IMR) share price is edging higher today
IMR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Imricor Medical Systems Inc
Imricor Medical Systems Inc is a medical device company engaged in addressing issues with traditional x-ray-guided ablation procedures through the development of MRI-guided technology. Its principal business activities are to design, manufacture and sell MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The products of the company include Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter and Vision-MR Dispersive Electrode.
IMR Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
27 Nov 2024 | $1.07 | $0.19 | 21.59% | 383,626 | $0.89 | $1.12 | $0.89 |
26 Nov 2024 | $0.88 | $0.01 | 1.14% | 84,591 | $0.88 | $0.92 | $0.88 |
25 Nov 2024 | $0.88 | $-0.06 | -6.45% | 200,977 | $0.95 | $0.95 | $0.87 |
22 Nov 2024 | $0.93 | $0.01 | 1.08% | 124,980 | $0.94 | $0.94 | $0.92 |
21 Nov 2024 | $0.93 | $-0.01 | -1.06% | 97,383 | $0.94 | $0.95 | $0.90 |
20 Nov 2024 | $0.94 | $0.05 | 5.65% | 175,069 | $0.89 | $0.94 | $0.87 |
19 Nov 2024 | $0.89 | $0.06 | 7.27% | 125,273 | $0.83 | $0.89 | $0.83 |
18 Nov 2024 | $0.83 | $0.01 | 1.23% | 117,095 | $0.83 | $0.85 | $0.83 |
15 Nov 2024 | $0.81 | $-0.04 | -4.71% | 252,314 | $0.85 | $0.87 | $0.81 |
14 Nov 2024 | $0.85 | $0.02 | 2.40% | 132,861 | $0.84 | $0.85 | $0.81 |
13 Nov 2024 | $0.84 | $-0.04 | -4.60% | 339,309 | $0.88 | $0.90 | $0.84 |
12 Nov 2024 | $0.87 | $0.06 | 7.41% | 433,430 | $0.83 | $0.89 | $0.83 |
11 Nov 2024 | $0.81 | $0.07 | 9.46% | 578,034 | $0.74 | $0.82 | $0.74 |
08 Nov 2024 | $0.74 | $0.04 | 5.71% | 51,429 | $0.72 | $0.74 | $0.71 |
07 Nov 2024 | $0.70 | $-0.02 | -2.78% | 15,938 | $0.72 | $0.72 | $0.70 |
06 Nov 2024 | $0.72 | $-0.05 | -6.49% | 28,944 | $0.75 | $0.75 | $0.69 |
05 Nov 2024 | $0.77 | $0.03 | 4.03% | 420,305 | $0.75 | $0.77 | $0.75 |
04 Nov 2024 | $0.75 | $0.11 | 17.32% | 140,142 | $0.69 | $0.75 | $0.68 |
01 Nov 2024 | $0.64 | $0.01 | 1.60% | 57,904 | $0.63 | $0.65 | $0.62 |
31 Oct 2024 | $0.63 | $-0.07 | -10.14% | 250,168 | $0.69 | $0.69 | $0.61 |
30 Oct 2024 | $0.69 | $0.00 | 0.00% | 24,710 | $0.70 | $0.71 | $0.69 |
29 Oct 2024 | $0.69 | $-0.02 | -2.82% | 32,454 | $0.71 | $0.71 | $0.68 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
06 Jun 2024 | Steve Wedan | Issued | 2,113,342 | $951,003 |
Issue of options.
|
22 May 2024 | Steve Wedan | Buy | 100,000 | $45,000 |
Off-market trade. CDIs
|
21 May 2024 | Peter McGregor | Issued | 107,556 | $47,862 |
Issue of securities. CDI
|
21 May 2024 | Mark Tibbles | Issued | 107,556 | $47,862 |
Issue of securities. CDIs
|
21 May 2024 | Anita Messal | Issued | 100,834 | $44,871 |
Issue of securities.
|
07 May 2024 | Peter McGregor | Buy | 100,000 | $48,368 |
On-market trade.
|
28 Feb 2024 | Peter McGregor | Issued | 78,271 | $35,221 |
Rights issue. 665,479 CDIs , as per announcement on 01-03-2024
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Peter McGregor | Non-Executive Director | May 2019 |
Mr McGregor has over 30 years of experience in senior finance and management roles, including having been a partner in the investment banking firm of Goldman Sachs JBWere and a managing director in the institutional banking & markets division of Commonwealth Bank of Australia. Mr McGregor is an experienced company director, and currently serves as a Director of Treasury Corporation of Victoria and True Infrastructure Management Pty Ltd.
|
Mr Steve Wedan | Chief Executive OfficerPresidentExecutive ChairmanExecutive Director | May 2006 |
Mr Wedan is responsible for the overall management and strategic direction of the Company. Mr Wedan has over 30 years of experience in the medical device industry including design engineering of MRI and ultrasound systems for GE Healthcare, as well as Vice President and Chief Technology Officer for Applied Biometrics Inc. Immediately prior to co-founding Imricor, Mr Wedan founded and operated a technical consulting company, Wedan Technologies Inc., from 2000-2006. Mr Wedan is a member of various international standards committees in the fields of MRI safety and the compatibility of implanted and interventional products in MRI. Mr Wedan currently serves on the Board of Directors of Medical Device Research Forum, Inc. and Water Rescue Innovations, Inc., as well as the Advisory Board of Poiesis Medical, LLC.
|
Mr Mark Tibbles | Non-Executive Deputy ChairmanNon-Executive Director | Sep 2014 |
Mr Tibbles is an entrepreneur, business owner, company director and active venture investor in and advisor to technology, life science and medical device companies. Mr Tibbles is currently a Board member of OMEDZA.com, Inc., FamGenix, and CorVent Medical, Inc.; an owner and managing member of STEM Fuse, LLC, one of the providers of digital K-12 STEM curriculum in the U.S.; and the Managing Director of Strategic Stage Ventures, LLC. Prior to his current roles, Mr Tibbles was a Board member of the Nerdery, LLC as well as an owner and member of Intuitive Technology Group until it was sold in 2017. Mr Tibbles was also a President and founder of PRC Consulting, Inc., a company specialising in the management and implementation of IT projects for Fortune 1000 Companies, from 1998 until 2013, when PRC was sold. He is member of Risk Committee.
|
Ms Anita Messal | Non-Executive Director | Mar 2021 |
Ms Messal has over 35 years of experience in the health care and benefits industry, most recently as the Chief Integration Officer at AccentCare where she was responsible for the integration of merged and acquired entities across all areas of the business. Ms Messal has experience in health plan services, health care delivery, care management, and benefits administration. She has worked with self-funded, fully insured and CMS funded care. Her customers and partners include large and mid-size employers, health plans, insurance carriers, brokers, resellers, enterprise software companies and consumers. Ms Messal has participated in fund raising from start-up through IPO and sale to strategic buyers and private equity. Anita has worked in both F100 and start up companies with experience in public, private and non-profit businesses. Her experience includes working in domestic and international markets, with time spent developing programs and partnerships in the United Kingdom and Europe. Ms Messal currently serves on the Board of Directors of Ideon. She is member of Risk Committee.
|
Mr Jeffrey Leighton | Non-Executive Director | Jul 2024 |
--
|
Mr Kobe Li | Company Secretary |
-
|
|
Gregg Stenzel | Chief Operating Officer |
-
|
|
Kobe Li | Company Secretary |
-
|
|
Kate Lindborg | Director of Clinical Affairs |
-
|
|
Greg Englehardt | Executive Director of Sales |
-
|
|
Nick Corkill | Vice President Corporate Strategy |
-
|
|
Dan Sunnarborg | Vice President of Engineering |
-
|
|
Jonathon Gut | Vice President of Finance and Chief Financial Officer |
-
|
|
Nick Twohy | Vice President of Marketing |
-
|
|
Vic Fabano | Vice President of Operations |
-
|
|
Jennifer Weisz | Vice President of Regulatory and Quality |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Citicorp Nominees Pty Limited <Domestic Hin A/C> | 21,527,041 | 11.44% |
HSBC Custody Nominees (Australia) Limited | 17,838,946 | 9.48% |
Warren G Herreid Ii | 9,486,098 | 5.04% |
Bnp Paribas Noms (Nz) Ltd | 9,002,900 | 4.78% |
Hsbc Custody Nominees (Australia) Limited A/C 2 | 8,544,746 | 4.54% |
Siemens Medical Solutions Usa Inc | 8,384,150 | 4.46% |
Hr Global Investments Llc | 6,879,579 | 3.66% |
Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 4,649,106 | 2.47% |
UBS Nominees Pty Ltd | 3,333,334 | 1.77% |
Kahr Foundation | 2,950,988 | 1.57% |
Steven R Wedan | 2,693,720 | 1.43% |
Maclay Group Pty Ltd <Maclay Longhurst Family A/C> | 1,761,113 | 0.94% |
Bauer Private Equity Fund Vi Llc | 1,696,555 | 0.90% |
Matthew James Banfield | 1,461,868 | 0.78% |
Steven R Wedan & Cherri J Wedan Jt Ten | 1,427,373 | 0.76% |
Merrill Lynch (Australia) Nominees Pty Limited | 1,358,832 | 0.72% |
Ronald D Berger | 1,300,000 | 0.69% |
Pacific Premier Trust Cust Fbo Jeffrey J Quinn Ira | 1,288,462 | 0.68% |
Stojanov Investment Pty Ltd <Stojanov Family A/C> | 1,236,363 | 0.66% |
Bradica Nominees Pty Ltd <L & J Bradica S/F A/C> | 1,185,750 | 0.63% |